Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?


Why are So Many Health Care Companies Moving to Ireland?

By  +Follow June 18, 2014 3:00AM
Tickers Mentioned:

Ireland, tax inversion, health care stocks, tax avoidance, overseas corporationsCovidien (COV) surged to a 52-week high of $86.75 per share on June 16, after rival medical device manufacturer Medtronic (MDT) announced it would buy the Irish company for $42.9 billion in a cash-and-stock deal. The combined company would have its executive offices in Dublin, but it would continue to stage most of its operations in Minneapolis, where Medtronic employs more than 8,000 people. Similarly, although Covidien is run from Mansfield, Massachusetts, it’s been incorporated in Ireland since 2009.

Why? It most likely comes down to the fact that the U.S. government has the highest corporate tax rate among developed nations at 35 percent. That’s what has many health care companies moving to Ireland. Or, at least, moving just enough of their operations there to avoid paying taxes in the United States.

Medtronic Not Alone

On top of Medtronic, there are more than 40 American companies that currently reincorporate in foreign countries or have plans to do so. In a recent wave of big moves, many health care companies have considered moving enough of their operations overseas to benefit from Ireland’s attractive 12.5% corporate tax rate.

Pfizer (PFE) , the largest U.S. drug maker, tried to acquire AstraZeneca (AZN) with a $117 billion bid in May 2014. The N.Y.-based company was seeking to lower its tax rate through the deal by moving its official headquarters to London, where AstraZeneca is based. While Pfizer was also planning to gain from AstraZeneca’s experimental immune therapy cancer drugs, a new class treatment that would have filled a hole in Pfizer’s product portfolio, it also seems certain the tax benefits were a major motivator.

The Pfizer deal failed when AstraZeneca shareholders balked at what they considered a low price for the company despite the deal having had the potential to be the largest inversion to date, but there have been plenty of other successful inversions involving multi-billion dollar valuations.

The pharmaceutical company Actavis (ACT) moved from New Jersey to Ireland by taking over Irish company Warner Chilcott in 2013, and then acquired Forest Labs of New York for $25 billion earlier this year. In December 2013, The Perrigo Company (PRGO) , the largest maker of private label over-the-counter medicines in the U.S., completed the acquisition of Elan Corporation for approximately $8.6 billion. The new combination will, undoubtedly, locate in Ireland, a move that would reduce its effective tax rate from 23.2 percent to 17percent and chalk up $150 million in annual savings. And Jazz Pharmaceuticals Inc. (JAZZ) moved from Palo Alto to Ireland after purchasing an Irish specialty drug maker Azur Pharma in 2011.

Taxes Motivating Overseas Moves

The “death and taxes” adage is appears to be applicable here. But while these companies can’t completely avoid paying taxes, they will certainly do whatever they can to avoid paying any more than they have to.

In the cases above, the companies all claimed that they would have more opportunities to further their international platform in a low-tax environment, especially via an Irish legal domicile (a territorial tax system) that would serve as an international hub. These transitions are made in the name of “protecting shareholders’ interests.” But is it true?

Takeovers by U.S. companies in low-tax environments have doubled in proportion to all overseas deals according to data compiled by Goldman Sachs Group Inc. analysts. The desire for such an arrangement, know as a tax inversion, is the main factor.

One big advantage of a tax inversion deal, except a lower statutory tax rate, is that deals can become more affordable. Once inverted, companies can more-easily use overseas cash to pay for a deal, and the earnings from any acquired company will also be taxed at the new lower rate.

As for Medtronic and Covidien, both companies have struggled to grow as hospitals and insurers push to control costs. In the U.S., the Affordable Care Act has put even more pressure on medical centers to work more efficiently and reduce repeat hospital admissions. Medtronic has struggled since 2010 with declining sales in its two major segments, including heart rhythm devices and spinal products for emerging questions about their safety and overuse.

“While the Covidien deal revolves around the tax advantages, Medtronic will gain by changing its legal residence to Dublin, that’s a part of a bigger strategy aimed at breaking loose from its historic dependence on heart pacemakers and defibrillators,” said Medtronic’s CEO Omar Ishrak in a conference.

Why Pharmaceutical Companies are on the Crest of this Wave

Similar transitions do happen in other industries. Global offshore contract driller Rowan Companies (RDC) moved its legal domicile to the United Kingdom in 2012, partially because the ability to remain competitive with the global effective tax rates of its peers. Insurance broker and consulting firm Aon Corp. (AON) moved from Chicago to London to be closer to the world’s largest insurance market and to benefit from a tax system where worldwide income is not taxed.

But why do so many of these deals involve pharma companies? These companies have seen years of consolidation among their customers, including hospitals and physician groups, and there has been a wave of mergers between hospital systems, as well as between hospitals and the practices of independent surgeons, over the past several years. As a result, hospitals have gained greater negotiating power with suppliers.

Pharma companies, in particular, prefer Ireland as their new home because the Green Isle boasts an encouraging tax regime for pharmaceutical manufacturers.

Another reason is that the Irish government provides a forum for good manufacturing practice-compliant sites with comparatively modest fees, a priority for most pharma companies looking to ensure cost-savings amid expiring patents.

Governments Unlikely to Stand Idle

The Irish government has begun to worry about the popularity of tax inversions. The country’s pillar of development policy may be used for purposes for which it was not intended, thus undermining Ireland’s insistence that it is not a tax haven and making it more difficult to defend its economic system in an international environment that is in the process of turning seriously against tax avoidance. The Irish authorities believe that the inversion trend is “push rather than pull”, implying that the high rate of U.S. tax rather than the low rate of Irish tax is driving the shift.

For the U.S., the trend threatens billions of dollars of tax revenues and raises “significant policy concerns,” in the words of the U.S. Treasury. Since 2010, U.S. purchases into the low-tax environments accounted for 15 percent of all overseas transactions with a value of $250 million or more, according to Goldman Sachs’ data. Without any changes in law, future deals will cost the U.S. an estimated $19.5 billion in tax revenue over the next 10 years.

As such, the federal government isn’t likely going to ignore these mergers forever. President Barack Obama has already made a proposal that would make inversion deals tougher. A U.S. company currently must buy a foreign company whose market value is at least 20 percent of the combined company, but President Obama’s proposal would raise that limit to 50 percent. In addition, Sen. Carl Levin (D-Mich.) and Senate Finance Chairman Ron Wyden (D-Ore.) both claimed in May that they plan to propose legislation that might curtail such deals.

Change in the Near Term Seems Unlikely

However, there’re little chances for doing any tax reform advancing in the near future. Any reform would likely have to include changing the rates paid by individuals and small businesses as well, and any changes to the tax system represent a political challenge that currently seems impossible to overcome.

In other words, companies like Medtronic and Covidien still have time to consider their escape from the U.S. tax system carefully.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.

Liked What You Read? Join Equities.com as a contributor and get eyeballs on your content FOR FREE!

Results for COV
Nicky Stokes
25 Nov 14 20:30:29
Great #Stock Newsletter on $PVH $COV $NRG $AIG #wealthmanagement http://t.co/lxNCxMEF3a
Lynell Dew
25 Nov 14 20:17:48
$COV Here are some Stocks to Watch $WTR $IACI $TRLA #economy http://t.co/o3JeUbepvJ
Donnell Isom
25 Nov 14 20:03:55
Insider Trading alerts on $SIG $STR $COV $USD #economy http://t.co/GVqlxgTZWS
Williemae Gerard
25 Nov 14 19:43:11
Are you Bullish on these #stocks $COV $APD $CIM $QLYS Goto http://t.co/Ga8TV9eAz2
Venice Poland
25 Nov 14 19:36:23
$BMS Small-cap stocks making 52-wk highs $GPN $COV $SLV #StockMarket http://t.co/tC6cyReQHo
Darin Nickerson
25 Nov 14 19:07:14
#Stock Market Reports you need on $ORCL $COV $IPG $CI Must see http://t.co/Rxj6fbduA0
Carlyn Mccloskey
25 Nov 14 18:39:39
Is it breakout time on $WMB $COV $APD $RAX #wallstreet http://t.co/GayxitwJan
Caitlin Cohen
25 Nov 14 18:23:11
Get great research on stocks $CPN $COV $ETFC $TUR Visit http://t.co/XSXLVl2h1y
Sheba Li
25 Nov 14 18:17:48
#Stocks you might want to sell $NEE $COV $GHC $CHTP Goto http://t.co/47pEpzsN6l
Phylicia Stine
25 Nov 14 18:09:32
Stocks I'm keeping my Eye on...should you? $CNX $GCI $COV $GAIN #personalfinance http://t.co/OcBrwf7d3z
25 Nov 14 18:00:04
Popular Stock Picks By Consensus: $COV $NKE $BBBY $MRK $GILD $BIDU $BRCD $NLY $ATVI $T $SYMC $AXP $MET $EMC $CMCSA http://t.co/Vv2VEnpBuv
Bertha Diaz
25 Nov 14 17:38:15
#Stocks you migh want to Sell $COV $NUS $THC $IR #liquidity http://t.co/FR6Jb1hWev
Espace MicroCaps
25 Nov 14 17:29:52
EspaceMC Idea Tracker $COV - Profile Price = 1.35$ and closed today @ 1.30$ for a negative return of 4%. Lumpy results but intriguing upside
Shante Lamm
25 Nov 14 17:27:06
$TUP Should you buy $WAG $COV $ARNA Check out http://t.co/GFN8ZI5Gsr
Nixon Domville
25 Nov 14 17:25:25
Would you like great research on stocks $COV $ETFC $EIX $GAIN #financialnews http://t.co/UspOB9jkKc
Dana Mcginnis
25 Nov 14 16:21:58
Shoud you sell or hold stocks like $COV $FMC $USM $ISRG Click http://t.co/uIj4d6Caa2
Darius Begay
25 Nov 14 16:10:19
Latest Earnings info on $TE $CVS $COV $ABX Try this http://t.co/LO6Qp2kTZD
Louella Ivy
25 Nov 14 16:09:26
Should you hold or add to $RGLD $COV $PTEN $BLOX #wealthmanagement http://t.co/WSQhr3XXzi
Necole Diaz
25 Nov 14 14:58:28
Great #Pennystock #research $HAR $WMB $COV $CBM Must see http://t.co/zxTAr0QW2X
Ashleigh Neuman
25 Nov 14 14:49:49
Are you thinking of Investing in $COV $PF $F $GAIN #financialnews http://t.co/xCiNRKBlcu
Donnell Isom
25 Nov 14 14:32:11
Todays movers to research $UFS $COV $INTU $FB View now http://t.co/FpujwCPRST
Hilde Phipps
25 Nov 14 14:03:42
Should you buy, sell or hold $COV $RE $AZO $SLW #wealthmanagement http://t.co/EYqcCd1sjc
Rozella Huffman
25 Nov 14 13:42:05
$TMHC Seeking the next hot #pennystock $INTA $COV $BLOX #Stock http://t.co/ILGHpR3T0Z
Cinda Mock
25 Nov 14 13:40:42
#Stocks to hold onto $ERIE $COV $WTR $CAG #financialnews http://t.co/aE4ddJrNA5
Varun Saxena
25 Nov 14 13:08:38
RT @FierceMedDev: Covidien gets 510(k) for peripheral balloon catheter aimed at hemodialysis patients http://t.co/Gxr6J3agZ7 by @VarunSaxen…
Laurene Haddock
25 Nov 14 13:04:35
$SCHW Free research on $CMI $COV $CHTP I suggest http://t.co/tmVsjOYzxx
25 Nov 14 13:04:11
UPDATED with info from $COV: Covidien gets 510(k) for peripheral balloon catheter aimed at hemodialysis patients http://t.co/yq2qKX8GNn
Demarcus Batson
25 Nov 14 13:03:36
Should you buy $BEAV $COV $IGT $RT Must see http://t.co/GSiAPuvr49
Rhona Keeling
25 Nov 14 12:39:29
Regretting your investment in $COV $RRD $RHT $AMZN View now http://t.co/qCzHqvuW8A
Leonie Machado
25 Nov 14 12:35:27
5 Stocks you should be watching $COV $FE $WEC $IR View now http://t.co/UVvAvC5vRo
Kristian Redmond
25 Nov 14 12:18:17
Stocks I'm keeping my Eye on...should you? $COV $HSIC $CA $DF Worth a look http://t.co/HAuTWcZCn7
Lanelle Fultz
25 Nov 14 12:01:35
Great #Pennystock #research $TE $A $COV $GAIN #overvalued http://t.co/IV0c8noOxq
Alycia Adamson
25 Nov 14 11:58:57
Get great research on stocks $UFS $COV $PPG $PCLN Check out http://t.co/XWWtwWL2HQ
25 Nov 14 11:55:06
$COV - Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions http://t.co/mahO1u5tMD
Audrey Machado
25 Nov 14 11:22:23
Looking for the next $AWAY $COV $CYT $DO #personalfinance http://t.co/nGyftv0G9v
Kassie Gauge
25 Nov 14 11:15:41
$HBAN Free research on $IR $COV $CRAY #liquidity http://t.co/zgl5urGYLc
Helena Sasser
25 Nov 14 10:39:31
Insider Trading alerts on $COV $PF $SWKS $BWP #financialnews http://t.co/fsSC20s4vW
Nicole Harris
25 Nov 14 10:34:35
RT @TheDealNewsroom: Medtronic is committed to closing its $42.9B purchase of rival medical device maker Covidien http://t.co/W8pm6vhD8m $M…
Market Int Center
25 Nov 14 10:18:18
Potential Covidien $COV Trade Targets 14.27% Return ( http://t.co/jZ9t8p9lmj )
Shirely Pence
25 Nov 14 10:16:43
$SCHW Todays Stocks you should Watch $CIT $COV $ISRG #wealthmanagement http://t.co/t6c1PqmFh2
Amy Reeves
25 Nov 14 10:13:04
Becton Dickinson's buyout of CareFusion should be more lucrative than expected, says SEC filing: http://t.co/DN8IyH6ks3 $BDX $CFN $MDT $COV
Orson Manns
25 Nov 14 09:47:35
Would you like great research on stocks $OCR $COV $MJN $CBM Check out http://t.co/WYX3vdL4v2
Chrissy Croteau
25 Nov 14 09:36:01
$PWR Are you considering selling $ROC $COV $CI #StockMarket http://t.co/bZTaI3rdZb
Farrah Ledoux
25 Nov 14 09:28:54
$COV Get more info on $LPLA $SNI $DUST #wallstreet http://t.co/KFn8XwhlNN
Ali Tyree
25 Nov 14 09:14:16
Are you looking for more winners like $COV $RPAI $ADM $IBM #equity http://t.co/p5Uqzj6yNd
Asha Carvalho
25 Nov 14 09:08:39
Dont want to lose like you did with $COV $CNP $AVGO $LGND Try this http://t.co/VJpGvup7Ue
Dana Mcginnis
25 Nov 14 09:02:15
Is it breakout time on $COV $MJN $MWV $PCLN Must have http://t.co/z3sbjgfg9P
25 Nov 14 08:56:44
$COV #bto JAN15 $105 Cs @ 1.94
25 Nov 14 08:56:16
Covidien plc: The stock is testing its highs. $COV http://t.co/W4A4OG6HEt http://t.co/rI4Lpco5Bq
25 Nov 14 08:36:29
RT @Calcbench: @Calcbench sees SURGICAL & MED INSTRUMENTS CapEx Up 7.7% YoY. $BAX $MMM $COV $SYK. https://t.co/F1w9841aHL #finance #BigData…
By  +Follow June 18, 2014 3:00AM



blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.